Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 5/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.42 |
| ▸ | ACACB | O00763 | 12/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099555 | 0.85 | FPR2 (0.47) | CHRM4FPR2PROKR1ACACBFFAR1 | |
| SCHEMBL12100367 | 0.84 | FPR2 (0.44) | CHRM4FPR2PROKR1ACACBFFAR1 | |
| SCHEMBL12099792 | 0.84 | FPR2 (0.39) | CHRM4FPR2PROKR1ACACBFFAR1 | |
| SCHEMBL12100122 | 0.81 | FPR2 (0.43) | CHRM4FPR2PROKR1ACACBFFAR1 | |
| SCHEMBL12099651 | 0.81 | FPR2 (0.42) | CHRM4FPR2PROKR1ACACBFFAR1 | |
| SCHEMBL12099671 | 0.81 | FPR2 (0.43) | CHRM4FPR2PROKR1ACACBFFAR1 | |
| SCHEMBL12099623 | 0.80 | MAPK14 (0.42) | CHRM4FPR2PROKR1ACACBFFAR1 | |
| SCHEMBL12099573 | 0.80 | FPR2 (0.47) | CHRM4FPR2PROKR1ACACBFFAR1 | |
| SCHEMBL12099552 | 0.78 | ACACB (0.49) | FPR2PROKR1ACACBFFAR1MAPK14 | |
| SCHEMBL12099684 | 0.77 | ACACB (0.42) | FPR2PROKR1ACACBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | CHRM4 1127/4885FPR2 419/4885PROKR1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.